Antithrombotic Management After Intracranial Hemorrhage

We present a thorough review of the current data available regarding management of antithrombotics after intracranial hemorrhage.Recent findingsThe most robust evidence comes from the investigators of the RESTART trial which reassured the safety of resuming antiplatelet therapy after ICH, namely in patients with prior indication and treatment with antithrombotics.SummaryWe conclude that based on available data, the risk of recurrent ICH is probably too small to exceed the found benefits of antiplatelet therapy in the secondary prevention of ischemic vascular disease.

http://link.springer.com/10.1007/s11936-019-0771-y

Source: Current Treatment Options in Cardiovascular Medicine - December 9, 2019 Category: Cardiology Source Type: research